Dyne Therapeutics Inc (NAS:DYN)
$ 26 0.05 (0.19%) Market Cap: 2.27 Bil Enterprise Value: 1.84 Bil PE Ratio: 0 PB Ratio: 4.68 GF Score: 37/100

Dyne Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2022 / 06:15PM GMT
Release Date Price: $15.17 (+1.74%)
Unidentified Participant

All right. Good afternoon, everyone. Very quickly for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. [Now with] that out of the way, welcome. Joined by Josh Brumm, President, CEO; Oxana Beskrovnaya -- did I get close to that? -- CSO; and Wildon Farwell, CMO of Dyne. First time having Dyne at the Morgan Stanley Healthcare Conference, and we're excited to have them here.

Let me very quickly set the stage. Dyne is a clinical stage muscle disease company focused on advancing life-transforming therapeutics for people living with genetically driven diseases. Company is applying its proprietary FORCE platform and now has two clinical stage programs in myotonic dystrophy Type 1 or DM1, as well as Duchenne muscular dystrophy or DMD. So, we're happy to have Dyne here. I think we'll jump right in. You had a really busy morning.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot